EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study

Tamar Berger, Tzippy Shochat, Shlomzion Aumann, Boaz Nachmias, Neta Goldschmidt, Nurit Horesh, Reut Harel, Ariel Aviv, Ella Shmerts, Uri Abadi, Shai Shimony, Pia Raanani und 2 weitere

Annals of Hematology · 2023

DOI: 10.1007/s00277-023-05306-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2023. Verfasst von Tamar Berger und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel. tamarberger29@gmail.com. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Febrile Neutropenia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The GALLIUM study showed a progression-free survival advantage of 7% in favor of obinutuzumab vs. rituximab-based immunochemotherapies as first-line therapy in follicular lymphoma (FL) patients. Yet, the toxicity appears to be increased with obinutuzumab-based therapy. This is a multicenter retrospective-cohort study including adult FL patients comparing the toxicity of first-line rituximab vs. obinutuzumab-based chemo-immunotherapies (R and O groups, respectively). We compared the best standard-of-care therapy used per time period, before and after obinutuzumab approval. The primary outcome was any infection during induction and 6 months post-induction. Secondary outcomes included rates of febrile neutropenia, severe and fatal infections, other adverse events, and all-cause mortality. Outcomes were compared between groups. A total of 156 patients were included in the analysis, 78 patients per group. Most patients received bendamustine (59%) or CHOP (31.4%) as adjacent chemotherapy. Half of the patients received growth-factor prophylaxis. Overall, 69 patients (44.2%) experienced infections, and a total of 106 infectious episodes were recorded. Patients in the R and O groups had similar rates of any infection (44.8% and 43.5%, p = 1), severe infections (43.3% vs. 47.8%, p = 0.844), febrile neutropenia (15% vs. 19.6%, p = 0.606), and treatment discontinuation, as well as similar types of infections. No covariate was associated with infection in multivariable analysis. No statistically significant difference was evident in adverse events of grades 3-5 (76.9% vs. 82%, p = 0.427). To conclude, in this largest real-life study of first-line treated FL patients comparing R- to O-based therapy, we did not observe any difference in toxicity during the induction and 6 months post-induction period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularFebrile NeutropeniaAdultHumansRituximabRetrospective StudiesCohort StudiesAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideImmunotherapyAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Chemo-immunotherapyFollicular lymphoma (FL)InductionObinutuzumabRituximab

Substanzen

RituximabBendamustine HydrochlorideobinutuzumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel. tamarberger29@gmail.com.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. tamarberger29@gmail.com.
  • Laboratory of Genome Maintenance, The Rockefeller University, New York, NY, USA. tamarberger29@gmail.com.
  • Rabin Medical Center, Bio-Statistical Unit, Beilinson Campus, Petah-Tikva, Israel.
  • Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.

Zitieren

APA

Berger, T., Shochat, T., Aumann, S., Nachmias, B., Goldschmidt, N., Horesh, N., Harel, R., Aviv, A., Shmerts, E., Abadi, U., Shimony, S., Raanani, P., Gafter-Gvili, A., & Gurion, R. (2023). Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study. Annals of Hematology. https://doi.org/10.1007/s00277-023-05306-2

Vancouver

Berger T, Shochat T, Aumann S, Nachmias B, Goldschmidt N, Horesh N, et al. Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study. Annals of Hematology. 2023. doi:10.1007/s00277-023-05306-2

BibTeX
@article{Berger2023,
  author = {Berger, Tamar and Shochat, Tzippy and Aumann, Shlomzion and Nachmias, Boaz and Goldschmidt, Neta and Horesh, Nurit and Harel, Reut and Aviv, Ariel and Shmerts, Ella and Abadi, Uri and Shimony, Shai and Raanani, Pia and Gafter-Gvili, Anat and Gurion, Ronit},
  title = {Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study},
  journal = {Annals of Hematology},
  year = {2023},
  doi = {10.1007/s00277-023-05306-2}
}
Kostenlos starten →